Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 2171 to 2180 of 2591 total matches.
Dexrazoxane for Cardiac Protection Against Doxorubicin
The Medical Letter on Drugs and Therapeutics • Nov 24, 1995 (Issue 962)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Dexrazoxane (Zinecard - Pharmacia) was recently approved by the US Food and Drug Administration (FDA) for protection against cardiac toxicity from (Adriamycin, and others) in women with metastatic breast cancer.
Bone Densitometry
The Medical Letter on Drugs and Therapeutics • Nov 22, 1996 (Issue 988)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Use of alendronate (Fosamax), estrogen and other drugs for prevention and treatment of osteoporosis (Medical Letter, 38:1, 1996) has been accompanied by widespread availability of bone density screening tests, not only in doctors offices and hospitals, but even in retail stores. Bone densitometry provides a quantitative measurement of bone mineralization that can be used to predict the risk of osteoporotic fractures.
Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • May 08, 1998 (Issue 1026)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Dolasetron (Anzemet - Hoechst Marion Roussel), a selective serotonin (5-HT3) receptor antagonist similar to ondansetron (Zofran) and granisetron (Kytril - Medical Letter, 36:61, 1994) is now available for both oral and intravenous use in prevention of nausea and vomiting due to cancer chemotherapy. A 5-HT3 antagonist plus dexamethasone (Decadron, and others) is the most effective regimen for prevention of acute vomiting caused by cancer chemotherapy. Dolasetron has also been approved by the FDA for prevention and treatment of postoperative nausea and...
Ginkgo Biloba for Dementia
The Medical Letter on Drugs and Therapeutics • Jun 19, 1998 (Issue 1029)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Extracts made from leaves of the ginkgo tree (Ginkgo biloba) are available in the uSA as deitary supplements, in France and Germany as licensed drugs and worldwide as herbal remedies for treatment of dementia and many other indications.
Prosorba Column for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Jul 30, 1999 (Issue 1058)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Prosorba, an antibody-adsorbing column used with plasmapheresis, has been approved by the FDA for treatment of moderate-to-severe rheumatoid arthritis in patients refractory or intolerant to methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs).
Docosanol Cream (Abreva) for Recurrent Herpes Labialis
The Medical Letter on Drugs and Therapeutics • Nov 13, 2000 (Issue 1092)
The Medical Letter
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 Main ...
Doconsanol 10% cream, a long-chain saturated alcohol, has been approved by the FDA for over-the-counter treatment of herpes labialis.
Prevention and Treatment of Pertussis
The Medical Letter on Drugs and Therapeutics • Sep 17, 2012 (Issue 1399)
The Medical Letter®
On Drugs and Therapeutics
Volume 54 (Issue 1399)
September 17, 2012 ...
The CDC has reported that many states are experiencing
a higher-than-usual incidence of pertussis this
year. The highest incidence has been in infants, but
the disease has also occurred in older children, adolescents,
and adults. Thirteen pertussis-related
deaths were reported through August 24; the majority
of these were in infants <3 months old.
Probiotics Revisited
The Medical Letter on Drugs and Therapeutics • Jan 07, 2013 (Issue 1407)
The Medical Letter®
On Drugs and Therapeutics
Volume 55 (Issue 1407)
January 7, 2013 ...
Probiotics are live, nonpathogenic microorganisms
(usually bacteria or yeasts) marketed as dietary supplements.
They have not been approved by the FDA for
any indication. Since our last article on this subject,
some new data have become available.
Diclegis for Nausea and Vomiting of Pregnancy
The Medical Letter on Drugs and Therapeutics • Aug 05, 2013 (Issue 1422)
The Medical Letter®
On Drugs and Therapeutics
Volume 55 (Issue 1422)
August 5, 2013 ...
The FDA has approved Diclegis (Duchesnay), a fixed-dose,
delayed-release combination of the H1-antihistamine
doxylamine and the vitamin B6 analog pyridoxine,
for treatment of nausea and vomiting of pregnancy in
women who do not respond to conservative management.
It is only available by prescription. Doxylamine
and pyridoxine, both currently available over the
counter, were previously available by prescription in a
fixed-dose combination (Bendectin) for morning sickness.
Bendectin was voluntarily withdrawn in the US in
1983 because of claims of teratogenicity that have
since been...
Hemgenix - A Gene Therapy for Hemophilia B
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
infusion. The drug should not be administered to
patients who test positive for factor IX inhibitors ...
Etranacogene dezaparvovec-drlb (Hemgenix – CSL
Behring), an adeno-associated virus vector-based
gene therapy, has been approved by the FDA for
treatment of hemophilia B in adults who currently
receive factor IX prophylaxis therapy or have had
life-threatening or repeated, serious, spontaneous
bleeding episodes. It is the first gene therapy to be
approved in the US for this indication.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):9-10 doi:10.58347/tml.2023.1668a | Show Introduction Hide Introduction